Human protein interaction networks of ancestral and variant SARS-CoV-2 in organ-specific cells and bodily fluids.

人类蛋白质相互作用网络:SARS-CoV-2 祖先型和变异型病毒在器官特异性细胞和体液中的相互作用

阅读:10
作者:Broderick Kirsten, Moutaoufik Mohamed Taha, Saccon Tatiana, Malty Ramy, Amin Shahreen, Phanse Sadhna, Joseph Thomson Patrick, Zilocchi Mara, Hosseinnia Ali, Istace Zoe, Hajikarimlou Maryam, Abrar Sakib, Fisher Jade, Brassard Raelynn, Perera Ranawaka, Kumar Anil, Aoki Hiroyuki, Rahmatbakhsh Matineh, Jessulat Matthew, Kobasa Darwyn, Dehne Frank, Prasad Bhanu, Gagarinova Alla, Joanne Lemieux M, Cochrane Alan, Houry Walid A, Aly Khaled A, Golshani Ashkan, Babu Mohan
Understanding SARS-CoV-2 human protein-protein interactions (PPIs) and the host response to infection is essential for developing effective COVID-19 antivirals. However, how the ancestral virus and its variants remodel virus-host protein assemblies in various organ-specific cells and bodily fluids remains unclear. Here, we conduct 639 affinity-purifications by tagging and expressing 28 SARS-CoV-2 and spike proteins from the ancestral virus and four variants in eight cell lines representing five mammalian organs and the immune system. Using mass spectrometry (MS), we identify both known and previously unreported SARS-CoV-2-human PPIs, highlighting similarities and differences across organ- or immune-derived cell lines and virus strains. Besides verifying the cell- and variant-specific PPIs, co-fractionation-MS analysis of COVID-19 patients' saliva confirm host PPI changes between SARS-CoV-2 strains. We discover that the NSP3 papain-like protease, a secreted protein, binds fibrinogen to induce abnormal blood clotting and interferon-induced proteins to evade host innate immune responses. Leveraging deep learning, we design peptide inhibitors that successfully blocked SARS-CoV-2 and variant replication in human liver cells, reversing virus-induced PPI alterations. Together, these findings provide molecular insights into SARS-CoV-2 biology, uncover reorganized viral-host protein assemblies during infection, and identify potential host therapeutic targets and inhibitors for developing antivirals against SARS-CoV-2 strains.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。